Latest BVF INC/IL Stock Portfolio
BVF INC/IL Performance:
2025 Q3: -7.54%YTD: -14.43%2024: -0.14%
Performance for 2025 Q3 is -7.54%, and YTD is -14.43%, and 2024 is -0.14%.
About BVF INC/IL and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, BVF INC/IL reported an equity portfolio of $2.5 Billions as of 30 Sep, 2025.
The top stock holdings of BVF INC/IL are KYMR, RVMD, PTGX. The fund has invested 12.6% of it's portfolio in KYMERA THERAPEUTICS INC and 7.5% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off IONIS PHARMACEUTICALS INC (IONS), VERASTEM INC (VSTM) and RAPT THERAPEUTICS INC (RAPT) stocks. They significantly reduced their stock positions in FORTE BIOSCIENCES INC (FBRX), CELCUITY INC (CELC) and AXSOME THERAPEUTICS INC (AXSM). BVF INC/IL opened new stock positions in NEKTAR THERAPEUTICS (NKTR), ABIVAX SA and STOKE THERAPEUTICS INC (STOK). The fund showed a lot of confidence in some stocks as they added substantially to STRUCTURE THERAPEUTICS INC, CIDARA THERAPEUTICS INC (CDTX) and IMMUNOCORE HLDGS PLC (IMCR).
The top stock holdings of BVF INC/IL are KYMR, RVMD, PTGX. The fund has invested 12.6% of it's portfolio in KYMERA THERAPEUTICS INC and 7.5% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off IONIS PHARMACEUTICALS INC (IONS), VERASTEM INC (VSTM) and RAPT THERAPEUTICS INC (RAPT) stocks. They significantly reduced their stock positions in FORTE BIOSCIENCES INC (FBRX), CELCUITY INC (CELC) and AXSOME THERAPEUTICS INC (AXSM). BVF INC/IL opened new stock positions in NEKTAR THERAPEUTICS (NKTR), ABIVAX SA and STOKE THERAPEUTICS INC (STOK). The fund showed a lot of confidence in some stocks as they added substantially to STRUCTURE THERAPEUTICS INC, CIDARA THERAPEUTICS INC (CDTX) and IMMUNOCORE HLDGS PLC (IMCR).
BVF INC/IL Annual Return Estimates Vs S&P 500
Our best estimate is that BVF INC/IL made a return of -7.54% in the last quarter. In trailing 12 months, it's portfolio return was -21.17%.
New Buys
| Ticker | $ Bought |
|---|---|
| nektar therapeutics | 72,638,300 |
| abivax sa | 47,376,800 |
| stoke therapeutics inc | 38,941,800 |
| compass therapeutics inc | 16,625,000 |
| pepgen inc | 8,847,300 |
| x4 pharmaceuticals inc | 7,639,400 |
| imagenebio inc | 6,537,130 |
New stocks bought by BVF INC/IL
Additions
| Ticker | % Inc. |
|---|---|
| structure therapeutics inc | 80.87 |
| cidara therapeutics inc | 79.83 |
| palvella therapeutics inc ne | 66.71 |
| immunocore hldgs plc | 53.7 |
| essa pharma inc | 33.37 |
| avalo therapeutics inc | 31.83 |
| kura oncology inc | 11.13 |
| sab biotherapeutics inc | 1.62 |
Additions to existing portfolio by BVF INC/IL
Reductions
| Ticker | % Reduced |
|---|---|
| forte biosciences inc | -88.89 |
| celcuity inc | -81.00 |
| axsome therapeutics inc | -71.2 |
| mirum pharmaceuticals inc | -45.85 |
| protagonist therapeutics inc | -20.25 |
| revolution medicines inc | -20.22 |
| septerna inc | -8.65 |
| zymeworks inc | -8.59 |
BVF INC/IL reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| ovid therapeutics inc | -1,271,380 |
| verastem inc | -14,128,400 |
| ionis pharmaceuticals inc | -75,597,800 |
| rapt therapeutics inc | -9,237,540 |
| ikena oncology inc | -5,368,800 |
BVF INC/IL got rid off the above stocks
Sector Distribution
BVF INC/IL has about 77.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 77.2 |
| Others | 22.8 |
Market Cap. Distribution
BVF INC/IL has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 35.2 |
| UNALLOCATED | 25.1 |
| SMALL-CAP | 20.5 |
| MICRO-CAP | 18.2 |
Stocks belong to which Index?
About 60.4% of the stocks held by BVF INC/IL either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 60.4 |
| Others | 39.6 |
BVF INC/IL Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of BVF INC/IL
BVF INC/IL has 46 stocks in it's portfolio. About 58.6% of the portfolio is in top 10 stocks. MLTX proved to be the most loss making stock for the portfolio. CELC was the most profitable stock for BVF INC/IL last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ANNX | annexon inc | 0.86 | 7,000,000 | 21,350,000 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 0.70 | 1,355,260 | 17,225,300 | added | 31.83 | ||
| AXSM | axsome therapeutics inc | 2.40 | 486,757 | 59,116,600 | reduced | -71.2 | ||
| CDTX | cidara therapeutics inc | 5.49 | 1,414,160 | 135,420,000 | added | 79.83 | ||
| CELC | celcuity inc | 1.32 | 658,421 | 32,526,000 | reduced | -81.00 | ||
| CGEM | cullinan therapeutics inc | 1.38 | 5,750,680 | 34,101,600 | unchanged | 0.00 | ||
| CMPX | compass therapeutics inc | 0.67 | 4,750,000 | 16,625,000 | new | |||
| ELDN | eledon pharmaceuticals inc | 0.66 | 6,293,280 | 16,299,600 | unchanged | 0.00 | ||
| EPIX | essa pharma inc | 0.09 | 11,668,500 | 2,228,680 | added | 33.37 | ||
| FBRX | forte biosciences inc | 0.04 | 65,350 | 980,250 | reduced | -88.89 | ||
| FDMT | 4d molecular therapeutics in | 1.63 | 4,629,290 | 40,228,500 | unchanged | 0.00 | ||
| FHTX | foghorn therapeutics inc | 1.05 | 5,302,000 | 25,926,800 | unchanged | 0.00 | ||
| GLUE | monte rosa therapeutics inc | 1.70 | 5,660,130 | 41,941,600 | unchanged | 0.00 | ||
| IKNA | imagenebio inc | 0.26 | 802,102 | 6,537,130 | new | |||
| IKNA | ikena oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IMCR | immunocore hldgs plc | 2.32 | 1,574,290 | 57,193,900 | added | 53.7 | ||
| IMUX | immunic inc | 0.27 | 7,652,970 | 6,746,860 | unchanged | 0.00 | ||
| IONS | ionis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IVA | inventiva sa | 0.16 | 686,040 | 3,972,170 | unchanged | 0.00 | ||
| KURA | kura oncology inc | 3.09 | 8,617,160 | 76,261,900 | added | 11.13 | ||